On February 18 , 2009 , Pharmos Corporation and its Israeli subsidiary , Pharmos Ltd . , entered into an Asset Purchase Agreement with Reperio Pharmaceuticals Ltd. for the sale of the patent rights and technical know-how related to the compound known as PRS-639,058 and certain follow-on molecules .